

## **Res. Asst. PhD EMEL MUTLU**

### **Personal Information**

**Email:** emelmutlu@erciyes.edu.tr

**Web:** <https://avesis.erciyes.edu.tr/emelmutlu/>

**Address:** erciyes üniversitesiç hastalıkları ana bilim dalı

### **Education Information**

Postgraduate, Ankara University, Tıp Fakültesi, Turkey 2005 - 2011

### **Foreign Languages**

English, B1 Intermediate

### **Research Areas**

Health Sciences, Medicine, Internal Medicine Sciences, Internal Diseases , Nephrology

### **Academic Titles / Tasks**

Research Assistant PhD, Erciyes University, Dahili Tıp Bil., İç Hastalıkları, 2012 - Continues

### **Published journal articles indexed by SCI, SSCI, and AHCI**

- I. **The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study**  
Yildirim H. C., Kutlu Y., MUTLU E., Aykan M. B., Korkmaz M., YALÇIN S., Sakalar T., Celayir O. M., Kayikcioglu E., Aslan F., et al.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.3, pp.258-265, 2024 (SCI-Expanded)
- II. **Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events**  
Onur I. D., MUTLU E., Sertesen E., Onder T., Duran A. O., İNANÇ M.  
IMMUNOTHERAPY, vol.16, pp.295-303, 2024 (SCI-Expanded)
- III. **The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey**  
AKYILDIZ A., Guven D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., YILDIZ İ., Iriagac Y., Turhal S., Akbas S., et al.  
Medicine (United States), vol.102, no.45, 2023 (SCI-Expanded)
- IV. **Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study**  
YILDIRIM H. Ç., MUTLU E., Chalabihev E., Ozen M., KESKINKILIÇ M., ÖN S., Celebi A., DURSUN B., Acar O., KAHRAMAN S., et al.

## Articles Published in Other Journals

### I. Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report

MUTLU E., ÖZKAN M., FIRAT S. T., COŞAR R.

ERCIYES MEDICAL JOURNAL, vol.45, no.1, pp.101-103, 2023 (ESCI)

## Refereed Congress / Symposium Publications in Proceedings

### I. Böbrek nakli hastalarında sitogenetik hasarın belirlenmesi malignite gelişimi için bir biyobelirteç olarak kullanılabilir mi?

ÜNAL A., MUTLU E., KİRAZ A., TAŞDEMİR A., ÜNAL T. D., KOÇYİĞİT I., SİPAHİOĞLU M. H., TOKGÖZ B., OYMAK O.

33. Ulusal Nefroloji, Hipertansiyon, Diyaliz ve Transplantasyon Kongresi,, Antalya, Turkey, 19 - 23 October 2016,  
pp.44

## Supported Projects

ÜNAL A., MUTLU E., KİRAZ A., Project Supported by Higher Education Institutions, Böbrek nakli hastalarında genetik hasarın incelenmesi, 2014 - 2016

## Metrics

Publication: 6